anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides an acinetobacter baumannii vaccine and a preparation method thereof, and relates to the technical field of biology. The vaccine comprises a Acinetobacter baumannii nucleoside diphosphate kinase NDK recombinant protein, and the amino acid sequence of the Acinetobacter baumannii nucleoside diphosphate kinase NDK recombinant protein is shown as SEQ ID NO. 3. The vaccine prepared by the NDK recombinant protein can be used for immunization through an intramuscular injection way, and the organism is stimulated to generate high-titer antibodies. Animal experiments prove that the genetic engineering recombinant monovalent vaccine has good immune protection effect on Acinetobacter baumannii infection. The method lays a foundation for further research of combined vaccines and multi-subunit vaccines, and plays an important role in development and application of vaccines and diagnostic kits.
Home Monitoring is fully enabled and continuous remote surveillance data is available to investigators. Patients will be treated according to a predefined anticoagulation plan, which uses the total duration of AF/AFL combined with patients' CHADS2 score to determine the start, stop, and restart of OAC.
PROSpect is a two-by-two factorial, response-adaptive, randomized controlled clinical trial of supine/prone positioning and conventional mechanical ventilation (CMV)/high-frequency oscillatory ventilation (HFOV). About 60 pediatric intensive care units (PICUs), two thirds U.S. and one third international, with at least 5 years of experience with prone positioning and HFOV in the care of pediatric patients with severe Pediatric Acute Respiratory Distress Syndrome (PARDS), that can provide back-up extracorporeal membrane oxygenation (ECMO) support, are participating. Eligible consecutive subjects with high moderate-severe PARDS will be randomized to one of four groups: supine/CMV, prone/CMV, supine/HFOV, prone/HFOV. Subjects who fail their assigned positional and/or ventilation therapy for either persistent hypoxia or hypercapnia may receive the reciprocal therapy while being considered for ECMO cannulation. Our primary outcome is ventilator-free days (VFD) through day 28, where non-survivors receive zero VFD. We hypothesize that children with severe PARDS treated with either prone positioning or HFOV will demonstrate ≥ 2 more VFD. Our secondary outcome is nonpulmonary organ failure-free days. We will also explore the interaction effects of prone positioning with HFOV on VFDs and also investigate the impact of these interventions on 90-day in-hospital mortality and, among survivors, the duration of mechanical ventilation, PICU and hospital length of stay, and the trajectory of post-PICU functional status and health-related quality of life (HRQL). Up to 600 subjects with severe PARDS will be randomized, stratified by age group and direct/indirect lung injury. Adaptive randomization will first occur after 300 patients are randomized and have been followed for 28 days, and every 100 patients thereafter. At these randomization update analyses, new allocation probabilities will be computed based on ongoing intention-to-treat trial results, increasing allocation to well performing arms and decreasing allocation to poorly performing arms. Data will be analyzed per intention-to-treat for the primary analyses and per-protocol received for primary, secondary and exploratory analyses.
A novel supply source of enzyme being useful for modification of phospholipids, etc.; a process for producing 2-acyl-lysophospholipid; a process for producing monoacylglycerol; a process for producing a ceramide; and a novel method of degumming an oil or fat. There is provided a novel microbe belonging to the genus Moritella sp. and capable of producing an enzyme having phospholipase A1 activity, phospholipase C activity, lysophospholipase C activity and sphingomyelin-lytic activity. By the use of this enzyme, phospholipids are hydrolyzed to thereby produce 2-acyl-lysophospholipid and diacylglycerol, and sphingomyelins are hydrolyzed to thereby produce ceramides. Further, an oil or fat is degummed.
FIELD: chemical and pharmaceutical industry. SUBSTANCE: milled kernel wood of Maachia amurensis is extracted with 95% ethanol at ratio 1:5 at 50-55 C. Extraction is repeated three times at infusion time 12-24 h, extracts are combined, evaporated, purified with heavy petroleum ether or methylene chloride at the ratio aqueous residue:solvent = 3-4:1. Then the end product is extracted with ethylacetate or butanol at ratio aqueous residue: solvent = 3:1. Yield is about 8%, hepatoprotective activity of preparation is higher as compared with that of silibinin. EFFECT: increased yield, enhanced hepatoprotective activity. 1 dwg
OBJECTIVES: Bitewing radiography is considered to be of high diagnostic value in caries detection, but owing to projections, lesions may remain undetected. The novel bitewing plus (BW +) technology enables scrolling through radiographs in different directions and angles. The present study aimed at comparing BW + with other 2D and 3D imaging methods in terms of sensitivity, specificity, and user reliability.
MATERIALS AND METHODS: Five human cadavers were used in this study. In three cadavers, natural teeth were transplanted post-mortem. BW + , two-dimensional (digital sensors, imaging plates, 2D and 3D bitewing radiographs) and 3D methods (high and low dose CBCT) were taken. Carious lesions were evaluated on 96 teeth at three positions (mesial, distal, and occlusal) and scored according to their level of demineralization by ten observers, resulting in 35,799 possible lesions across all observers and settings. For reference, µCT scans of all teeth were performed.
RESULTS: Overall, radiographic evaluations showed a high rate of false-negative diagnoses, with around 70% of lesions remaining undetected, especially enamel lesions. BW + showed the highest sensitivity for dentinal caries and had comparatively high specificity overall.
CONCLUSIONS: Within the limits of the study, BW + showed great potential for added diagnostic value, especially for dentinal caries. However, the tradeoff of diagnostic benefit and radiation exposure must be considered according to each patient's age and risk.
BACKGROUND: Aberrant alternative splicing (AS) is a pervasive event during colorectal cancer (CRC) development. SF3B3 is a splicing factor component of U2 small nuclear ribonucleoproteins which are crucial for early stages of spliceosome assembly. The role of SF3B3 in CRC remains unknown.
METHODS: SF3B3 expression in human CRCs was analyzed using publicly available CRC datasets, immunohistochemistry, qRT-PCR, and western blot. RNA-seq, RNA immunoprecipitation, and lipidomics were performed in SF3B3 knockdown or overexpressing CRC cell lines. CRC cell xenografts, patient-derived xenografts, patient-derived organoids, and orthotopic metastasis mouse models were utilized to determine the in vivo role of SF3B3 in CRC progression and metastasis.
RESULTS: SF3B3 was upregulated in CRC samples and associated with poor survival. Inhibition of SF3B3 by RNA silencing suppressed the proliferation and metastasis of CRC cells in vitro and in vivo, characterized by mitochondria injury, increased reactive oxygen species (ROS), and apoptosis. Mechanistically, silencing of SF3B3 increased mTOR exon-skipped splicing, leading to the suppression of lipogenesis via mTOR-SREBF1-FASN signaling. The combination of SF3B3 shRNAs and mTOR inhibitors showed synergistic antitumor activity in patient-derived CRC organoids and xenografts. Importantly, we identified SF3B3 as a critical regulator of mTOR splicing and autophagy in multiple cancers.
CONCLUSIONS: Our findings revealed that SF3B3 promoted CRC progression and metastasis by regulating mTOR alternative splicing and SREBF1-FASN-mediated lipogenesis, providing strong evidence to support SF3B3 as a druggable target for CRC therapy.
The invention provides green external ointment for remedying skin disease, which is prepared from pure natural material. The invention has the components with the weight percentage content as follows: 20 to 30 percent of ozone, 100 percent of olive oil or flaxseed oil, 0.01 to 0.03 percent of lipophilic complex nano silver and 5 to 15 percent of hydrogenated castor oil.The external ointment has the following use method: cleaning the afflicted part, extruding the ointment on a dressing and then sticking the dressing on the afflicted part for 2 to 3 times everyday. The dressing is the sticking film with a groove in the middle. Non-woven cloth is embedded in the groove. The invention also provides a preparation method and a device of the external ointment. The invention has the advantages of good and quick treatment effect, small toxic and side effect, fast recovery and no operation trauma. The liquid extracted from the pure natural material stores the ozone molecule with a certain thickness with special technology and uses the ozone to remedy skin disease. The invention uses physical process and manufacture method without any chemical reaction.
Eligible subjects will be enrolled in one of the 4 arms of the RCT and followed for 6 months, with the primary outcome of out-of-range INRs. Subjects will be given a Med-eMonitor to connect to their home phone line. For all subjects, these will be used to measure daily adherence. Subjects in the incentive group will be eligible for a daily lottery prize only if, prior to the lottery being resolved, their adherence device has registered adherence to their prescribed warfarin regimen. Subjects in the MM group will have the reminder/feedback features of the Med-eMonitor turned on to provide reminders to take their warfarin as prescribed and standardized messages that will be used to provide feedback in response to their adherence. Subjects in the combined group will be exposed to both the lottery and the activated Med-eMonitor. This trial is a randomized controlled trial.

Both men and women who are at least 18 years of age and have been prescribed anticoagulation medication are eligible to participate.
The goal of this study is to implement and evaluate a randomized pilot study of a 4-month Nutrition-enhanced CHW intervention in primary care patients with nutrition insecurity and poorly controlled hypertension. The nutrition intervention will be added to the pre-existing Massachusetts General Hospital CHW hypertension (Basic CHW) that provides basic hypertension education, coaching about adherence to medications and primary care visits, and home BP cuffs and promotion of BP self-monitoring over the course of approximately 4 months. The CHW nutrition intervention curriculum is tailored to the needs and preferences of a food-insecure population with limited resources. Nutrition education materials will be provided to participants, including a booklet of nutrition information and a summarized version of key points on a brochure that they can use as a quick reference when grocery shopping. Nutrition education will focus on reducing sodium, saturated fats, and added sugars and increasing fruits, vegetables, and whole grains. Much of the educational material is based on a traffic-light system. These topics are organized into four modules: nutrition label reading, grocery shopping, meal-planning, and healthy cooking.
PURPOSE: To prepare an inhibitor of blood platelet aggregation and a therapeutic agent for thromboembolism comprising an ingredient of Magnolia kobus DC. as an active ingredient. CONSTITUTION: This inhibitor of blood platelet aggregation or therapeutic agent for thromboembolism comprises a compound represented by formula I (A is an aromatic group having a lower alkyl or a lower alkoxy as a substituent group or formula II; R1 is a lower alkoxy; R2 and R3 are each H or allyl; R4 is H or a lower alkoxy) or formula III (A is an aromatic group having a lower alkoxy as a substituent group) which is an ingredient of Magnolia kobus DC., e.g. denudatin B, veraguensin or fargesone as an active ingredient.  The compounds are obtained by drying the Magnolia kobus DC. which is a Chinese medicine or drying, then pulverizing or powdering the dried Magnolia kobus DC., partitioning and extracting the resultant pulverized or powdery material with alcohols, ketones, chloroform, etc., or a mixed solvent thereof, distilling off the organic solvent from the prepared organic layer under a reduced pressure, treating the residue by silica gel chromatography and concentrating the resultant fraction eluted with the single or the mixed solvent.
The aims of this project are to: (1) test a method that could increase personal endurance and reduce excessive rise in blood carbon dioxide during underwater exercise in divers; and (2) understand the mechanisms by which red blood cells transport oxygen and carbon dioxide and their possible effects on exercise capacity. During underwater exercise, personal endurance capacity and elevated blood PCO2 are key parameters that affect a diver's safety and performance. Unlike exercise on dry land, hypercapnia often occurs during dives and can impair cognitive function and predispose the diver to central nervous system (CNS) oxygen toxicity and convulsions underwater. Some people intrinsically have low ventilatory chemosensitivity, and are more likely to develop hypercapnia during a dive. Lack of stamina may also be a mission-critical variable, and both endurance and the ability to control blood carbon dioxide depend on the respiratory muscle (mainly diaphragm) function, for which endurance capacity is related to mitochondrial number. Previous studies from our lab have demonstrated increased mitochondrial biogenesis with training while breathing a low, sub-toxic (200 ppm) level of carbon monoxide. In this study we will test the effect of daily respiratory muscle training with and without added carbon monoxide on respiratory muscle power, diaphragm thickness, respiratory muscle endurance and exercise endurance during a subsequent dive to 50 feet of sea water. Arterial PCO2 and lactic acid levels will be measured during exercise tests before and after training. Transport of O2 and CO2 through erythrocyte cell membranes occurs mostly through channels. Erythrocytes from volunteers in this study will be tested for O2 and CO2 permeability, and to correlate gas transport efficiency with exercise performance and blood PCO2.
The most effective drug, doxorubicin (DOX), is widely used worldwide for clinical application as an anticancer drug. DOX-induced cytotoxicity is characterized by mitochondrial dysfunction. There is no alternative treatment against DOX-induced cardiac damage despite intensive research in the present decades. Ohwia caudata has emerged as a potential herbal remedy that prevents from DOX-induced cytotoxicity owing to its pharmacological action of sustaining mitochondrial dynamics by attenuating oxidative stress and inducing cellular longevity. However, its underlying mechanisms are unknown. The novel treatment provided here depends on new evidence from DOX-treated H9c2 cells, which significantly enhanced insulin-like growth factor (IGF) II receptor (IGF-IIR) pathways that activated calcineurin and phosphorylated dynamin-related protein 1 (p-Drp1) at ser616 (p-Drp1[ser616]); cells undergo apoptosis due to these factors, which translocate to mitochondria and disrupt their function and integrity, and in terms of herbal medicine treatment, which significantly blocked these phenomena. Thus, our findings indicate that maintaining integrity of mitochondria is an essential element in lowering DOX-induced cytotoxicity, which further emphasizes that our herbal medicine can successfully block IGF-IIR pathways and could potentially act as an alternative mechanism in terms of cardioprotective against doxorubicin.
Circulating microRNAs (miRNAs) are linked to the onset and progression of type 1 diabetes mellitus (T1DM), thus representing potential disease biomarkers. In this study, we employed a multiplatform sequencing approach to analyze circulating miRNAs in an extended cohort of prospectively evaluated recent-onset T1DM individuals from the INNODIA consortium. Our findings reveal that a set of miRNAs located within T1DM susceptibility chromosomal locus 14q32 distinguishes two subgroups of individuals. To validate our results, we conducted additional analyses on a second cohort of T1DM individuals, confirming the identification of these subgroups, which we have named cluster A and cluster B. Remarkably, cluster B T1DM individuals, who exhibit increased expression of a set of 14q32 miRNAs, show better glycemic control and display a different blood immunomics profile. Our findings suggest that this set of circulating miRNAs can identify two different T1DM subgroups with distinct blood immunomics at baseline and clinical outcomes during follow-up.
The present invention belongs to the fields of pharmacy and clinical pharmacy, and relates to a cyclopeptide containing arginine-glycine-aspartic acid (RGD) sequence, an active target liposome thereof, a preparation method thereof and the purpose thereof. The structure of the cyclopeptide conforms to the requirements for being a ligand. The cyclopeptide is looped by amido bonds, so that the cyclopeptide has stable space conformation and is difficult to degrade. One end of the cyclopeptide contains active sulfhydryl group which is convenient for carrying outmodification. The artificially synthesized functional peptide has small molecular weight, so that the immune reaction is difficult to evoke. The cyclopeptide is used as the ligand to be combined with an integrin receptor on the surface of a hepatic stellate cell (HSC) to construct the active target liposome. The present invention realizes the cell targeted therapy of experimental hepatic fibrosis by a receptor medium approach. The present invention makes an RGD cyclopeptide-marked liposome carrying interferon targeted to the fibrosis liver. Tested in or outside the animal body, the present invention has the purpose of treating the hepatic fibrosis with high therapeutic effect.
The present invention relates to a system for the generation of antibody fusion proteins which has utility in the production of recombinant molecules that possess novel, clinically relevant biological activity. The antibody fusion proteins of the invention may be used therapeutically to deliver biologically active ligands to a desired tissue.      In particular embodiments of the invention, the antibody fusion protein comprises a biologically active ligand which is a lymphokine, including, in a specific embodiment, interleukin-2. Because interleukin-2 induces lymphocyte proliferation, fused antibody that targets interleukin-2 (IL-2) to a malignant or infected tissue can produce localized amplification of the immune response toward the diseased tissue, and thereby facilitate the destruction of the infected or malignant tissue. In a specific embodiment of the invention, a fused antibody is produced which comprises a variable region of the anti-tumor antigen monoclonal antibody L6 and active IL-2.      Additional embodiments of the invention relate to fused antibodies which comprise an immunoglobulin variable region and a biologically active ligand which is a-non-lymphokine cellular factor. In a specific embodiment of the invention, a fused antibody is produced which comprises a variable region of the anti-tumor antigen monoclonal antibody L6 and active platelet factor 4, a molecule associated with antagonism of angiogenesis, inhibition of suppressor T lymphocyte development, chemotaxis and heparin binding.
<P>PROBLEM TO BE SOLVED: To obtain an ameliorant for blood fluidity that is safe and inexpensive and continuously and readily taken and a food and beverage that ameliorates blood fluidity.  <P>SOLUTION: The ameliorant for blood fluidity comprises catechin as an active ingredient. The food and beverage have amelioration effect on blood fluidity. The ameliorant for blood fluidity and the food and beverage keep blood fluidity in a high state for several hours after intake, namely keeps blood viscosity in a low state. Consequently, crisis risks by rising early morning liable to cause particularly ischemic diseases are reduced by taking the ameliorant for blood fluidity or the food and beverage before going to bed. The ameliorant for blood fluidity and the food and beverage are inexpensive. When the ameliorant for blood fluidity or the beverage is used as a tea-based beverage, it is reasonably taken without largely changing a preceding lifestyle habit.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Previous studies suggest that sulfation of proteoglycans plays a crucial role in the normal development of cartilage and bone and could therefore be crucial in the genesis of the disease. The main catalytic machinery responsible for the biosynthesis and breakage of sulfate esters in the proteoglycans consists of various enzymes and transporters. Mutations in Sphingosine Kinase 1 (SK1) and Sphingosine Kinase 2 (SK2) genes that encode the transmembrane transporters of sulfate or enzymes that are involved in 3'-phosphoadenosine 5'-phosphosulfate (PAPS) synthesis have been identified as the cause of several inherited diseases that all have skeletal system deformities.

Connections between chest wall deformities with syndromes (e.g. Marfan, Noonan), anomalies (e.g. Poland, Moebius) or associations (e.g. Cantrell Pentalogy, PHACE) are well known. In contrast, there have so far been hardly any genetic studies of the isolated congenital chest wall deformities. Epidemiological data are insufficient and only a few groups deal with the inheritance and the incidence of this disease when it occurs in isolation.
The invention describes the composition and preparation of an extract, which has only a yellowish colour, from peat, which is suitable, owing to the absence of the typical dark brown-coloured humic acids and fulvic acids of the peat, and the presence of the complete lipoid fraction of the peat, to be employed as carrier of the peat active substances in uncoloured cosmetic products. Isopropyl myristate and liquid paraffin are mentioned as solvents for the peat lipoids. The ratio of the extractant to the finely ground air-dried peat is 2.5:1 to 6:1. Extraction takes place at 70 DEG -95 DEG C with continuous stirring. The extract must be filtered off immediately and quickly because peat lipoid constituents precipitate out of the extract again on cooling. However, these can be resuspended again satisfactorily in the extract at room temperature.